These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 24635957

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R, Larkin J, Gore M, Fearfield L.
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR, De Los Santos JF, Conry RM.
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [Abstract] [Full Text] [Related]

  • 11. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [Abstract] [Full Text] [Related]

  • 12. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL, Lopez IE, Desai SR.
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [Abstract] [Full Text] [Related]

  • 13. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK.
    Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
    [Abstract] [Full Text] [Related]

  • 14. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE, Hepper DM, Linette GP, Hurst EA, Lu D, Lind AC, Cornelius LA.
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
    Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O.
    Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
    [Abstract] [Full Text] [Related]

  • 17. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
    Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu A, Petrella T, Collet E, Vabres P.
    Br J Dermatol; 2015 Oct; 172(5):1454-5. PubMed ID: 25384395
    [No Abstract] [Full Text] [Related]

  • 18. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
    Lang N, Weisser A, Enk A, Hassel JC.
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
    [No Abstract] [Full Text] [Related]

  • 19. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
    Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Oct 01; 20(19):4994-5000. PubMed ID: 25096067
    [Abstract] [Full Text] [Related]

  • 20. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.
    Melanoma Res; 2014 Aug 01; 24(4):415-8. PubMed ID: 24933605
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.